Harmony Biosciences

Feb 25, 2025

•

Dec 31, 2024

Harmony Biosciences Q4 2024 Earnings Report

Harmony Biosciences reported strong financial results for Q4 2024, with net product revenues reaching a record $201.3 million and GAAP net income at $49.5 million.

Key Takeaways

Harmony Biosciences reported a record $201.3 million in net product revenues for the fourth quarter of 2024. GAAP net income for the quarter was $49.5 million, or $0.85 earnings per diluted share. The company ended the year with $576 million in cash, cash equivalents and investments.

Net product revenues for Q4 2024 were $201.3 million, a 20% increase compared to the same period in 2023.

GAAP net income for Q4 2024 was $49.5 million, or $0.85 earnings per diluted share, compared to $26.6 million, or $0.45 earnings per diluted share, for the same period in 2023.

Non-GAAP adjusted net income for Q4 2024 was $63.0 million, or $1.08 earnings per diluted share, compared to $42.8 million, or $0.73 per diluted share, for the same period in 2023.

The company ended the year with $576 million in cash, cash equivalents and investments.